This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss. It has combined expertise in otology, gene therapy and inner ear drugdelivery to meet the requirements of individuals with disabling hearing loss globally.
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drugdelivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drugdelivery.
On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in DrugDelivery, a free one-hour industry webinar.
In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drugdelivery.
Paris, will open in May (18-19) with connectivity, sustainability and user experience identified as the key trends in 2022 influencing innovation across pharmaceutical packaging and drugdelivery. Pharmapack Europe will be held as Smart Event to enhance the benefits for global attendees, providing a hybrid experience that extends the.
The post Maculus Therapeutix welcomes Privity FZ LLE and Prepares Capital Raise for Novel DrugDelivery Platform appeared first on Pharma Mirror Magazine. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc. Capable of delivering any FDA approved.
FDA recently released a much-anticipated draft guidance to address these frequent questions: Essential DrugDelivery Outputs for Devices Intended to Deliver Drugs and Biological Products. Drugdelivery includes successful product preparation and the initiation, progression, and completion of dose delivery.
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
Clinical-stage drugdelivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a â10 million deal.
Why is pulmonary drugdelivery a complex challenge? Pulmonary delivery is highly specialized, and despite our vast and growing understanding of respiratory diseases and aerosol technologies, developing new and improved inhaled medicines still presents a number of challenges, particularly in getting the drug delivered to its target.
at Northwestern University—has developed novel technology with the potential to change the future of drugdelivery. A team of scientists—led by Yamin Zhang, Ph.D., and Colin Franz, MD, Ph.D., at Shirley Ryan AbilityLab and John Rogers, Ph.D.,
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA has also recently launched the Software Pre-Certification Pilot Program to provide an efficient regulatory framework for developers of SaMD products.
A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
Ceapro has extended a partnership underway to carry out a further research project with McMaster University for developing an inhalable immuno-therapeutic/-prophylactic for Covid-19-induced lung fibrosis. This project is intended to develop therapies for people suffering from Covid-19’s long-term effects.
DrugDelivery Devices Symposium. We have the distinct privilege of unveiling Oxford Global’s DrugDelivery Devices Symposium, taking place on the 10th of March, 2021. Discuss Combination Product Development & Engineering with leading experts such as Andrew Yum , United Therapeutics and Ning Yu , Biogen.
Workshop will be on ‘Ophthalmic DrugDeliveryDevelopment – Trials and Tribulations’. Ophthalmic DrugDelivery is compelling for many reasons, including the major issue of patient compliance and tolerability of therapies. Hosted by Brian Levy, CEO, Ocunexus Therapeutics. About the workshop leader.
Genentech’s ocular implant drugdelivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
Samyang has entered into a strategic partnership agreement with LG Chem to develop new cancer therapeutics using Samyang’s technology, NanoReady. LG Chem will use the technology for the development of innovative mRNA-based cancer therapeutics with maximised therapeutic efficacy.
Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.
Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
After proving the merits of its drugdelivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner. Medincell and AbbVie inked a development and licensing pact to create up to six long-acting injectables, Medincell said Wednesday.
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to the long-acting drugdelivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
The purpose of writing this review on floating drugdelivery systems (FDDS) was to The recent developments of FDDS including the physiological and formulation variables affecting gastric retention, approaches to design single-unit and multiple-unit floating systems, and their classification and formulation aspects are covered in detail.
Fear of needles, injection-associated infection and pain are responsible for patients skipping doses, which encourages the development of new delivery strategies that combine efficacy with limited side effects to treat patients adequately.
Interestingly, over the past few years, drugdevelopers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
Novartis has formed a strategic collaboration with drugdelivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.
Sorrento Technologies, a biotech firm developing novel treatments for COVID-19 and aggressive cancers such as melanoma, has received FDA clearance to start a research collaboration together with Mayo Clinic.
Global Biotechnology, DrugDevelopment and DrugDelivery Systems Nanoparticles Markets, 2019-2020 & 2025 – ResearchAndMarkets.com Global Biotechnology, DrugDevelopment and DrugDelivery Systems Nanoparticles Markets, 2019-2020 & 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Nanoparticles in Biotechnology, (..)
Texas A&M associate professor Akhilesh Gaharwar and graduate student Patrick Lee are developing a new class of hydrogels that can leverage light for drugdelivery and regenerative medicine treatments. However, once inside, they can be challenging […].
Ophthalmic technology firm Eyenovia and Formosa Pharmaceuticals have entered a collaboration agreement to develop new ophthalmic therapeutics. The collaboration will combine the Optejet dispensing technology of Eyenovia with the APNT nanoparticle formulation platform of Formosa to develop topical therapeutics.
US-based development-stage biopharmaceutical firm Satsuma Pharmaceuticals is developing STS101, a unique nasal powder formulation of the anti-migraine drug dihydroergotamine mesylate, for the treatment of acute migraine.
Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® DrugDevelopment in Advanced DrugDelivery Reviews Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® DrugDevelopment in Advanced DrugDelivery Reviews … Continue reading →
Oramed Pharmaceuticals, a company focused on the development of oral drugdelivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.
Therefore, medical technology is rapidly evolving, enabling more advanced and patient-friendly methods of drugdelivery. In the pursuit of creating patient-centric healthcare solutions, the medical industry has witnessed a groundbreaking advancement in drugdelivery with the emergence of large volume wearable injectors.
In a promising advancement, scientists from the University of North Carolina at Chapel Hill and Emory University have developed a novel drugdelivery system using synthetic amyloid beta (AÎ) peptides.
has unveiled its Alternative Methods Advancement Project (AMAP), a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing. Charles River Laboratories International, Inc.
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drugdelivery technology to enable development of “ultra long-acting” medicines for HIV ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drugdelivery technology to … Continue reading →
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content